TriangleNCT02761187 · OUTCOME
Number of Participants With Global Health Status Scale/Quality of Life (QoL) Among MM Participants
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Baseline up to 5 years
What was measured
The Global Health Status scale/QoL scale included 2 questions measured with a 7-point numeric rating scale (very poor to excellent). Raw scores are converted into scale scores ranging from 0 to 100. A higher score represents better HRQoL.
Analysis population: As the study was early terminated data was not collected for this outcome measure.
Groups in this outcome
1st Line of Therapy
The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
2nd Line of Therapy
The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
3rd Line of Therapy
The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
4th Line of Therapy
The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
>4th Line of Therapy
The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
Unknown
Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
| Group | Source count |
|---|---|
| 1st Line of Therapy | 0 |
| 2nd Line of Therapy | 0 |
| 3rd Line of Therapy | 0 |
| 4th Line of Therapy | 0 |
| >4th Line of Therapy | 0 |
| Unknown | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- calculate Pct
- false
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- units
- Participants
- description
- The Global Health Status scale/QoL scale included 2 questions measured with a 7-point numeric rating scale (very poor to excellent). Raw scores are converted into scale scores ranging from 0 to 100. A higher score represents better HRQoL.
- groups
- description
- The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG000
- title
- 1st Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG001
- title
- 2nd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG002
- title
- 3rd Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG003
- title
- 4th Line of Therapy
- description
- The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG004
- title
- >4th Line of Therapy
- description
- Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
- id
- OG005
- title
- Unknown
- population Description
- As the study was early terminated data was not collected for this outcome measure.
- reporting Status
- POSTED
- time Frame
- Baseline up to 5 years
- title
- Number of Participants With Global Health Status Scale/Quality of Life (QoL) Among MM Participants
- type
- PRIMARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice